Soleno Therapeutics Inc (NASDAQ:SLNO) — Market Cap & Net Worth
Market Cap & Net Worth: Soleno Therapeutics Inc (SLNO)
Soleno Therapeutics Inc (NASDAQ:SLNO) has a market capitalization of $2.72 Billion ($2.72 Billion) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #5238 globally and #1657 in its home market, demonstrating a 0.08% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Soleno Therapeutics Inc's stock price $52.87 by its total outstanding shares 51718149 (51.72 Million). Analyse Soleno Therapeutics Inc (SLNO) cash conversion ratio to see how efficiently the company converts income to cash.
Soleno Therapeutics Inc Market Cap History: 2015 to 2026
Soleno Therapeutics Inc's market capitalization history from 2015 to 2026. Data shows change from $7.18 Billion to $2.73 Billion (-10.39% CAGR).
Index Memberships
Soleno Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.11% | #127 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.01% | #571 of 3165 |
Weight: Soleno Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Soleno Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Soleno Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
12.58x
Soleno Therapeutics Inc's market cap is 12.58 times its annual revenue
Latest Price to Earnings (P/E) Ratio
114.63x
Soleno Therapeutics Inc's market cap is 114.63 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $3.14 Billion | $1.45 Million | -$12.07 Million | 2165.64x | N/A |
| 2017 | $1.40 Billion | $-1.55 Billion | -$15.67 Million | -0.90x | N/A |
| 2025 | $2.39 Billion | $190.41 Million | $20.89 Million | 12.58x | 114.63x |
Competitor Companies of SLNO by Market Capitalization
Companies near Soleno Therapeutics Inc in the global market cap rankings as of May 4, 2026.
Key companies related to Soleno Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Soleno Therapeutics Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Soleno Therapeutics Inc's market cap moved from $7.18 Billion to $ 2.73 Billion, with a yearly change of -10.39%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.73 Billion | +14.19% |
| 2025 | $2.39 Billion | +3.00% |
| 2024 | $2.32 Billion | +11.68% |
| 2023 | $2.08 Billion | +1932.83% |
| 2022 | $102.40 Million | -67.80% |
| 2021 | $318.07 Million | -78.76% |
| 2020 | $1.50 Billion | -34.35% |
| 2019 | $2.28 Billion | +71.93% |
| 2018 | $1.33 Billion | -5.00% |
| 2017 | $1.40 Billion | -55.56% |
| 2016 | $3.14 Billion | -56.22% |
| 2015 | $7.18 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Soleno Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.72 Billion USD |
| MoneyControl | $2.72 Billion USD |
| MarketWatch | $2.72 Billion USD |
| marketcap.company | $2.72 Billion USD |
| Reuters | $2.72 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Soleno Therapeutics Inc
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeut… Read more